Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014

Summary

Global Markets Directs, Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/hospital-acquired-methicillin-resistant-staphylococcus-aureus-mrsa-infections-pipeline-review-h1-2014

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198031

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/198031

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Cell Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Directs, Cell Therapeutics, Inc. - Product Pipeline Review - 2014, provides an overview of the Cell Therapeutics, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cell Therapeutics, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/cell-therapeutics-inc-product-pipeline-review-2014

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Download Full Report with TOC:  http://www.marketresearchreports.biz/sample/sample/198061

Scope

- The report provides brief overview of Cell Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cell Therapeutics, Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Cell Therapeutics, Inc.s pipeline products

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/198061

Reasons to buy

- Evaluate Cell Therapeutics, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cell Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cell Therapeutics, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cell Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cell Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cell Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Access Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Directs, Access Pharmaceuticals, Inc. - Product Pipeline Review - 2014, provides an overview of the Access Pharmaceuticals, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Access Pharmaceuticals, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/access-pharmaceuticals-inc-product-pipeline-review-2014

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198053

Scope

- The report provides brief overview of Access Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Access Pharmaceuticals, Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Access Pharmaceuticals, Inc.s pipeline products

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/198053

Reasons to buy

- Evaluate Access Pharmaceuticals, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Access Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Access Pharmaceuticals, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Access Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Access Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Access Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

China Smartphone Market to 2015: Mobile Handset Sales by Technology and by Generation

"China Smartphone Market to 2015: Mobile Handset Sales by Technology and by Generation" report provides a top-level overview and detailed insights into the operating environment for mobile operators. It is an essential tool for companies active across the telecom value chain in China and for new companies that may be considering entering the market.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/china-smartphone-market-to-2015-mobile-handset-sales-by-technology-and-by-generation

Key Findings
- Demographics - Statistical data on China population, households, businesses, nominal GDP, nominal GDP per Capita, consumer price inflation, exchange rates (local currency and US dollar)
- Mobile subscriptions and penetration by population
- Mobile handset sales by quarter
- Mobile handset revenue and average selling price
- Mobile handset sales volume by: type of customer, category, price band, technology and generation, air interface and by feature

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198085

Synopsis
This report offers a concise breakdown of China operating environment, with both historic data and forecasts to 2015. The report contains quantitative data which covers:

- Demographics - data on China population, households, businesses, nominal GDP, nominal GDP per Capita, consumer price inflation, exchange rates (local currency and US dollar)
- Mobile subscriptions and penetration by population
- Mobile handset sales by quarter
- Mobile handset revenue and average selling price
- Mobile handset sales volume by: type of customer, category, price band, technology and generation, air interface and by feature

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/198085

Since 1986, Pyramid Research has compiled an extensive database on the telecommunications markets in Asia, Africa, the Middle East, Europe, North America and Latin America. The core components of this database mainly include:
Regulatory
- Interviews with top officials at regulatory agencies.
- Statistical data published by governments and regulatory agencies.
- Copies of telecom laws and amendments.
- Copies of tariff schedules, interconnection regulations and universal service requirements.
Operators
- Interviews with key officials in strategic planning, marketing, network planning and financial planning.
- Extensive surveys conducted with operators to determine key network statistics, investment, technology rollout plans, subscribers by service, tariff plans and service offerings.
- Internal statistics and bulletins published by operators.
Vendors
- Interviews with key officials within vendors both at in-country offices and in-company headquarters.

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2014

This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2014

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198021

Scope

• The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
• The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects 
• A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/198021

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Directs, CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - 2014, provides an overview of the CardioVascular BioTherapeutics, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CardioVascular BioTherapeutics, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/cardiovascular-biotherapeutics-inc-product-pipeline-review-2014

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/198071

Scope

- The report provides brief overview of CardioVascular BioTherapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CardioVascular BioTherapeutics, Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CardioVascular BioTherapeutics, Inc.s pipeline products

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/198071

Reasons to buy

- Evaluate CardioVascular BioTherapeutics, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CardioVascular BioTherapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CardioVascular BioTherapeutics, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CardioVascular BioTherapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CardioVascular BioTherapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CardioVascular BioTherapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz

Asthma - Pipeline Review, H1 2014

This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.

Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/asthma-pipeline-review-h1-2014

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/197994

Scope

• The report provides a snapshot of the global therapeutic landscape of Asthma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
• The report reviews key players involved in the therapeutics development for Asthma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects 
• A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Asthma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/197994

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Asthma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact US:

Office: United States

State Tower 90 State Street, Suite 700 Albany, NY 12207 United States Toll Free: 866-997-4948 Tel: +1-518-618-1030 E: sales@marketresearchreports.biz